Compare Amgen, Inc. (AMGN) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Star Bulk Carriers Corp — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Star Bulk Carriers Corp trades at $25.69 (market cap $2.94B). The key difference: Amgen, Inc. is far larger — about 66.7× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays the higher dividend (3.91%). Which is the better fit depends on your goals.
| AMGN | SBLK | |
|---|---|---|
Market Cap | $196.12B | $2.94B |
Sector | Health | Industrials |
52-Week High | $388.16 | $28.21 |
52-Week Low | $271.18 | $16.79 |
Enterprise Value | $241.41B | $3.64B |
Dividend Yield | 2.77% | 3.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Star Bulk Carriers (SBLK) trades at $26.35, up 1.82% today, with a neutral technical signal and bullish moving averages. The company reported strong Q1 2026 earnings of $0.56 per share, beating estimates, and maintains a dividend payout. Revenue grew to $1.1 billion in 2026, with net income margin improving to 13.01%. Analyst consensus is bullish with 14 buy ratings.
SBLK presents a positive outlook with earnings beats and dividend returns, but faces risks from dry bulk market volatility and economic cycles. The stock's valuation at a P/E of 21.08 is reasonable given growth, yet investor caution is warranted on global trade fluctuations impacting shipping demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
